Coherus Oncology (CHRS) Projected to Post Quarterly Earnings on Monday

Coherus Oncology (NASDAQ:CHRS) is projected to post its Q4 2025 results before the market opens on Monday, March 9th. Analysts expect Coherus Oncology to post earnings of ($0.31) per share and revenue of $14.0930 million for the quarter. Parties can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Wednesday, March 11, 2026 at 5:00 PM ET.

Coherus Oncology Stock Down 1.2%

Shares of NASDAQ CHRS opened at $1.67 on Monday. The company has a current ratio of 1.24, a quick ratio of 1.23 and a debt-to-equity ratio of 0.42. The business has a 50-day moving average of $1.73 and a 200-day moving average of $1.52. The firm has a market capitalization of $249.61 million, a price-to-earnings ratio of 1.26 and a beta of 1.05. Coherus Oncology has a 12 month low of $0.71 and a 12 month high of $2.62.

Hedge Funds Weigh In On Coherus Oncology

Large investors have recently added to or reduced their stakes in the business. Quarry LP bought a new stake in Coherus Oncology in the third quarter worth $26,000. Blair William & Co. IL purchased a new position in shares of Coherus Oncology in the fourth quarter worth about $27,000. BNP Paribas Financial Markets lifted its stake in shares of Coherus Oncology by 108.2% in the 3rd quarter. BNP Paribas Financial Markets now owns 26,620 shares of the biotechnology company’s stock valued at $44,000 after acquiring an additional 13,832 shares during the last quarter. Corient Private Wealth LLC boosted its holdings in Coherus Oncology by 20.0% during the 2nd quarter. Corient Private Wealth LLC now owns 60,000 shares of the biotechnology company’s stock valued at $44,000 after acquiring an additional 10,000 shares during the period. Finally, Jane Street Group LLC bought a new position in Coherus Oncology during the 2nd quarter worth approximately $46,000. Hedge funds and other institutional investors own 72.82% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on CHRS shares. Oppenheimer started coverage on shares of Coherus Oncology in a report on Thursday, January 22nd. They issued an “outperform” rating and a $10.00 price target on the stock. Wall Street Zen upgraded shares of Coherus Oncology from a “sell” rating to a “hold” rating in a research report on Saturday, November 8th. Three analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $5.51.

Coherus Oncology Company Profile

Coherus Oncology, Inc is a commercial-stage biopharmaceutical company focused on the development, manufacturing and commercialization of biologic therapies for oncology support and immuno-oncology. Founded in 2010 and headquartered in Redwood City, California, Coherus specializes in biosimilar versions of established oncology agents as well as novel immunotherapy candidates.

The company’s lead marketed products include Udenyca (pegfilgrastim-cbqv) and Fulphila (pegfilgrastim-jmdb), biosimilars to Amgen’s Neulasta, which are designed to reduce the incidence of infection in patients undergoing myelosuppressive chemotherapy.